NEW YORK (GenomeWeb News) – Med BioGene today said that it and its commercial partner, Precision Therapeutics, have settled litigation with Signal Genetics and its Respira Health subsidiary, ending a dispute over an alleged breach of contract that began more than two years ago.

Under the terms of the agreement announced today, Precision will make an undisclosed payment to Signal Genetics and Respira on or by Jan. 6, 2014. Following the payment, Signal Genetics and Respira will dismiss and withdraw all of their legal claims made against Med BioGene and Precision.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

May
15
Sponsored by
Tecan

This webinar will discuss how an algorithm-driven synthetic biology system can enable engineering of biological systems for a range of applications.

Jun
20
Sponsored by
PerkinElmer

In this webinar, Michael Quail of the R&D Sequencing team at the Wellcome Trust Sanger Institute will provide an expert perspective on library prep for next-generation sequencing.

Jun
28
Sponsored by
PerkinElmer

This webinar will review a standardized, high-throughput, and fully automated library prep protocol for human metagenomic analysis.